{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T13:25:42Z","timestamp":1783517142314,"version":"3.55.0"},"reference-count":211,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The therapeutic landscape for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) has been profoundly transformed by the advent of novel antibody therapies. These include antibody-drug conjugates (ADCs) and various novel iterations. Each therapy is at a different stage of clinical development, with several agents now approved for clinical use, others in late-stage trials, and a robust pipeline of preclinical candidates. This review will provide an overview of the antibody-based therapies, focusing on their molecular targets and clinical context in lung cancer and the future of this rapidly emerging field.<\/jats:p>","DOI":"10.3389\/fonc.2026.1814095","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T13:03:41Z","timestamp":1783515821000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Innovative use of therapeutic antibodies in lung cancer: the current landscape of ADCs and other antibody-based therapies"],"prefix":"10.3389","volume":"16","author":[{"given":"Matthew","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, City of Hope Comprehensive Cancer Center","place":["Duarte, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Lovly","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, City of Hope Comprehensive Cancer Center","place":["Duarte, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00869-w","article-title":"Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment","volume":"25","author":"Zippelius","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104979","article-title":"Bystander effect in antibody-drug conjugates: Navigating the fine line in tumor heterogeneity","volume":"216","author":"Wang","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-21-0580","article-title":"Cellular-resolution imaging of bystander payload tissue penetration from antibody-drug conjugates","volume":"21","author":"Khera","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1632705","article-title":"Another power of antibody-drug conjugates: immunomodulatory effect and clinical applications","volume":"16","author":"Shi","year":"2025","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-014-9684-6","article-title":"Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality","volume":"17","author":"Hock","year":"2015","journal-title":"AAPS J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00876-4","article-title":"How to select IgG subclasses in developing anti-tumor therapeutic antibodies","volume":"13","author":"Yu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17091164","article-title":"Strategic and chemical advances in antibody-drug conjugates","volume":"17","author":"Alradwan","year":"2025","journal-title":"Pharmaceutics"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody-drug conjugate-based therapeutics: State of the science","volume":"111","author":"Birrer","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.1c00572","article-title":"Impact of drug conjugation on thermal and metabolic stabilities of aglycosylated and N-glycosylated antibodies","volume":"33","author":"Yamazoe","year":"2022","journal-title":"Bioconjug Chem"},{"key":"B11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40164-024-00493-8","article-title":"Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice","volume":"13","author":"Zhou","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12088-020-00896-1","article-title":"In vitro cytotoxicity study of cyclophosphamide, etoposide and paclitaxel on monocyte macrophage cell line Raw 264.7","volume":"60","author":"Yadav","year":"2020","journal-title":"Indian J Microbiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114408","article-title":"A comprehensive review of key factors affecting the efficacy of antibody drug conjugate","volume":"161","author":"Samantasinghar","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41698-022-00338-9","article-title":"Antibody-drug conjugates in lung cancer: dawn of a new era","volume":"7","author":"Coleman","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3212","article-title":"Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index","volume":"33","author":"Lyon","year":"2015","journal-title":"Nat Biotechnol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.8b00177","article-title":"Impact of payload hydrophobicity on the stability of antibody-drug conjugates","volume":"15","author":"Buecheler","year":"2018","journal-title":"Mol Pharm"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-17-3202","article-title":"Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody-drug conjugates","volume":"78","author":"Zhao","year":"2018","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-16-0343","article-title":"Optimization of a PEGylated glucuronide-monomethylauristatin E linker for antibody-drug conjugates","volume":"16","author":"Burke","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2020.114932","article-title":"Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through PEGylation","volume":"392","author":"Simmons","year":"2020","journal-title":"Toxicol Appl Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1039\/d2sc05678j","article-title":"Compact hydrophilic electrophiles enable highly efficacious high DAR ADCs with excellent in vivo PK profile","volume":"14","author":"Ochtrop","year":"2023","journal-title":"Chem Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.targ-19-a097","article-title":"Abstract A097: Tubulysin ADC payloads: An antimitotic drug class that retains activity in multidrug resistant models","volume":"18","author":"Burke","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.7b00243","article-title":"Stabilizing a tubulysin antibody-drug conjugate to enable activity against multidrug-resistant tumors","volume":"8","author":"Staben","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2021.06.012","article-title":"Duocarmycin-based antibody-drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress","volume":"26","author":"Yao","year":"2021","journal-title":"Drug Discov Today"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2020.127640","article-title":"Evaluation of PNU-159682 antibody drug conjugates (ADCs)","volume":"30","author":"Holte","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"key":"B26","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1158\/1538-7445.am2021-921","article-title":"Abstract 921: Combination of antibody-targeted amanitin conjugates (ATAC) with immune checkpoint inhibitors shows synergistic therapeutic effect in vitro and in vivo","volume":"81","author":"Decker","year":"2021","journal-title":"Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddtec.2018.08.005","article-title":"Amanitins and their development as a payload for antibody-drug conjugates","volume":"30","author":"Pahl","year":"2018","journal-title":"Drug Discov Today Technol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c01791","article-title":"Degrader-antibody conjugates: Emerging new modality","volume":"66","author":"Hong","year":"2023","journal-title":"J Med Chem"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012500","article-title":"Where does ISAC (immune-stimulating antibody conjugates) go from here","volume":"13","author":"Fu","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00652-y","article-title":"Radiotheranostics in oncology: current challenges and emerging opportunities","volume":"19","author":"Bodei","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202406.1116.v1","article-title":"Radioimmunotheragnosis in cancer research","volume":"16","author":"Garaulet","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02041-6","article-title":"Radiopharmaceuticals and their applications in medicine","volume":"10","author":"Zhang","year":"2025","journal-title":"Signal Transd Targ Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00013","article-title":"Antibody-drug conjugates in lung cancer: recent advances and implementing strategies","volume":"41","author":"Passaro","year":"2023","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1101\/2021.01.19.427340","article-title":"Tandem-cleavage linkers improve the in vivo stability and tolerability of antibody-drug conjugates","volume":"32","author":"Chuprakov","year":"2021","journal-title":"Bioconjug Chem"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1021\/bc0600214","article-title":"Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates","volume":"17","author":"Jeffrey","year":"2006","journal-title":"Bioconjug Chem"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.1c00124","article-title":"Enzyme-agnostic lysosomal screen identifies new legumain-cleavable ADC linkers","volume":"32","author":"Miller","year":"2021","journal-title":"Bioconjug Chem"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-17-2391","article-title":"Cathepsin B is dispensable for cellular processing of cathepsin B-cleavable antibody-drug conjugates","volume":"77","author":"Caculitan","year":"2017","journal-title":"Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17040561","article-title":"Linkers having a crucial role in antibody-drug conjugates","volume":"17","author":"Lu","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1038\/s41467-018-04982-3","article-title":"Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice","volume":"9","author":"Anami","year":"2018","journal-title":"Nat Commun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-0283","article-title":"Molecular pathways and mechanisms of HER2 in cancer therapy","volume":"29","author":"Raghav","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00924-9","article-title":"HER2-targeted therapies beyond breast cancer - an update","volume":"21","author":"Yoon","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100490","article-title":"Clinicopathologic and molecular characteristics of HER2 (ERBB2)-altered non-small cell lung cancer: implications for precision medicine","volume":"37","author":"Lee","year":"2024","journal-title":"Mod Pathol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30122645","article-title":"HER2 in non-small cell lung cancer (NSCLC): Evolution of the therapeutic landscape and emerging drugs-a long way to the top","volume":"30","author":"Trillo Aliaga","year":"2025","journal-title":"Molecules"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae151","article-title":"FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations","volume":"29","author":"Mehta","year":"2024","journal-title":"Oncologist"},{"key":"B45","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial","volume":"41","author":"Goto","year":"2023","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial","volume":"25","author":"Smit","year":"2024","journal-title":"Lancet Oncol"},{"key":"B48","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.43107","article-title":"Trastuzumab deruxtecan for ERBB2-mutant metastatic non-small cell lung cancer with or without brain metastases: a secondary analysis of randomized clinical trials","volume":"8","author":"Janne","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.16_suppl.tps9137","article-title":"Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non\u2013small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04)","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.12.080","article-title":"Trastuzumab deruxtecan in patients with HER2-overexpressing non-small cell lung cancer: results from part 1 of the open-label, multicenter, phase 1b DESTINY-Lung03 trial","author":"Planchard","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.09.1073","article-title":"P3.18.58 Trastuzumab deruxtecan + pembrolizumab as first-line treatment in HER2-overexpressing, PD-L1 Tps <50% NSCLC (DESTINY-Lung06)","volume":"20","author":"Janne","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(25)00012-9","article-title":"Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study","volume":"26","author":"Li","year":"2025","journal-title":"Lancet Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12943-018-0796-y","article-title":"Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18020207","article-title":"Targeting mesenchymal-epidermal transition (MET) aberrations in non-small cell lung cancer: current challenges and therapeutic advances","volume":"18","author":"Deng","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(09)70137-8","article-title":"Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors","volume":"10","author":"Karamouzis","year":"2009","journal-title":"Lancet Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155379","article-title":"c-MET pathway in human Malignancies and its targeting by natural compounds for cancer therapy","volume":"128","author":"Mohan","year":"2024","journal-title":"Phytomedicine"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01051-9","article-title":"Evolving roles of MET as a therapeutic target in NSCLC and beyond","volume":"22","author":"Lee","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33159","article-title":"The METeoric rise of MET in lung cancer","volume":"126","author":"Friedlaender","year":"2020","journal-title":"Cancer"},{"key":"B59","article-title":"FDA grants accelerated approval to telisotuzumab vedotin-TLLV for NSCLC with high c-met protein overexpression","year":"2025","journal-title":"US Food Drug Admin"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1200\/jco.24.00720","article-title":"Telisotuzumab vedotin monotherapy in patients with previously treated c-met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"8512","DOI":"10.1200\/jco.2025.43.16_suppl.8512","article-title":"Telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein\u2013targeting antibody-drug conjugate (ADC), in patients (pts) with advanced EGFR-mutated (MT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase 1 study","volume":"43","author":"Camidge","year":"2025","journal-title":"J Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1314","article-title":"1257MO ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (Pts) with advanced EGFR wildtype (WT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase I study","volume":"35","author":"De Miguel","year":"2024","journal-title":"Ann Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.16_suppl.tps8655","article-title":"Phase 1b\/2 study evaluating telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with budigalimab in patients (pts) with advanced non-squamous (NSQ) non-small cell lung cancer (NSCLC) with no prior treatment for advanced disease and no actionable genomic alterations","volume":"43","author":"Camidge","year":"2025","journal-title":"J Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108296","article-title":"Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer","volume":"239","author":"Liu","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010087","article-title":"The relationship between trop-2, chemotherapeutic drugs, and chemoresistance","volume":"25","author":"Koltai","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-24-4855","article-title":"Extracellular domain shedding of TROP2 activates EGFR signaling to drive prostate cancer metastasis","volume":"85","author":"Liu","year":"2025","journal-title":"Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.151","article-title":"The Trop-2 signalling network in cancer growth","volume":"32","author":"Guerra","year":"2013","journal-title":"Oncogene"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188902","article-title":"Targeting Trop-2 in cancer: Recent research progress and clinical application","volume":"1878","author":"Qiu","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B69","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2025.1293","article-title":"Expression of membrane targets for therapeutics in RET-positive non-small cell lung cancer","volume":"11","author":"Marinello","year":"2025","journal-title":"JAMA Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0321555","article-title":"Trop-2 expression in non-small cell lung cancer","volume":"20","author":"Kuo","year":"2025","journal-title":"PloS One"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15647","article-title":"Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes","volume":"8","author":"Inamura","year":"2017","journal-title":"Oncotarget"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1200\/jco-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-lung01 study","volume":"43","author":"Ahn","year":"2025","journal-title":"J Clin Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1200\/jco-24-01349","article-title":"Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-lung05 study","volume":"43","author":"Sands","year":"2025","journal-title":"J Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"8593","DOI":"10.1200\/jco.2024.42.16_suppl.8593","article-title":"Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced\/metastatic non-small cell lung cancer (a\/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05","volume":"42","author":"Lisberg","year":"2024","journal-title":"J Clin Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.06.002","article-title":"A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC","volume":"20","author":"Ahn","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0230","article-title":"TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC","volume":"19","author":"Levy","year":"2023","journal-title":"Future Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1721624","article-title":"TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naive locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations","volume":"15","author":"Newsom-Davis","year":"2025","journal-title":"Front Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2409621","article-title":"TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab +\/- platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer","volume":"20","author":"Okamoto","year":"2024","journal-title":"Future Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-22-0375","article-title":"Antibody-drug conjugate sacituzumab govitecan drives efficient tissue penetration and rapid intracellular drug release","volume":"22","author":"Kopp","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.72.1894","article-title":"Therapy of advanced non-small-cell lung cancer with an SN-38-anti-trop-2 drug conjugate, sacituzumab govitecan","volume":"35","author":"Heist","year":"2017","journal-title":"J Clin Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1200\/jco.24.00733","article-title":"Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III EVOKE-01 study","volume":"42","author":"Paz-Ares","year":"2024","journal-title":"J Clin Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.10.016","article-title":"First-line sacituzumab govitecan plus pembrolizumab in metastatic NSCLC: PD-L1 TPS less than 50% and more than or equal to 50% Cohorts of the EVOKE-02 study","author":"Reck","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03638-2","article-title":"Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1\/2 and phase 2 trials","volume":"31","author":"Zhao","year":"2025","journal-title":"Nat Med"},{"key":"B84","article-title":"Sacituzumab tirumotecan in EGFR-TKI-resistant, EGFR-mutated advanced NSCLC","author":"Fang","year":"2025","journal-title":"N Engl J Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"8529","DOI":"10.1200\/jco.2025.43.16_suppl.8529","article-title":"Sacituzumab tirumotecan (sac-TMT) in combination with tagitanlimab (anti-PD-L1) in first-line (1L) advanced non-small-cell lung cancer (NSCLC): Non-squamous cohort from the phase II OptiTROP-Lung01 study","volume":"43","author":"Fang","year":"2025","journal-title":"J Clin Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.09.012","article-title":"TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study","volume":"43","author":"Zhong","year":"2025","journal-title":"Cancer Cell"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-02142","article-title":"Ifinatamab deruxtecan in patients with extensive-stage small cell lung cancer: primary analysis of the phase II IDeate-lung01 trial","author":"Rudin","year":"2025","journal-title":"J Clin Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03600-2","article-title":"A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1\/1b trial","volume":"31","author":"Ma","year":"2025","journal-title":"Nat Med"},{"key":"B89","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1158\/1538-7445.am2023-596","article-title":"Abstract 596: Development and assessment of a novel tumor microenvironment activable linker (TMALIN) ADC platform for solid tumor treatments","volume":"83","author":"Cai","year":"2023","journal-title":"Cancer Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.09.049","article-title":"OA06.04 safety and efficacy of ABBV-706, a seizure-related homolog protein 6-targeting antibody-drug conjugate, in R\/R SCLC","volume":"20","author":"Byers","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1200\/jco.2025.43.16_suppl.3041","article-title":"ZL-1310, a DLL3 ADC, in patients with extensive stage small cell lung cancer: Ph1 trial update","volume":"43","author":"Patel","year":"2025","journal-title":"J Clin Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.09.046","article-title":"OA06.01 A first-in-human phase 1 study of SHR-4849 (IDE849), a DLL3-directed antibody-drug conjugate, in relapsed SCLC","volume":"20","author":"Cheng","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.12.028","article-title":"Phase 2 open-label study of sacituzumab govitecan as second-line therapy in patients with extensive-stage SCLC: results from TROPiCS-03","volume":"20","author":"Dowlati","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2019.06.008","article-title":"Mechanisms of receptor tyrosine-protein kinase erbB-3 (ERBB3) action in human neoplasia","volume":"189","author":"Black","year":"2019","journal-title":"Am J Pathol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3390\/cells12212517","article-title":"HER3: toward the prognostic significance, therapeutic potential, current challenges, and future therapeutics in different types of cancer","volume":"12","author":"Majumder","year":"2023","journal-title":"Cells"},{"key":"B96","doi-asserted-by":"publisher","first-page":"7406","DOI":"10.1038\/s41598-019-43678-6","article-title":"EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients","volume":"9","author":"Scharpenseel","year":"2019","journal-title":"Sci Rep"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.4081\/oncol.2018.355","article-title":"HER3 signaling and targeted therapy in cancer","volume":"12","author":"Mishra","year":"2018","journal-title":"Oncol Rev"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-3359","article-title":"HER3 augmentation via blockade of EGFR\/AKT signaling enhances anticancer activity of HER3-targeting patritumab deruxtecan in EGFR-mutated non-small cell lung cancer","volume":"28","author":"Yonesaka","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2021.39.15_suppl.9007","article-title":"Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer","volume":"12","author":"Janne","year":"2022","journal-title":"Cancer Discov"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01476","article-title":"HERTHENA-lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J Clin Oncol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"8506","DOI":"10.1200\/jco.2025.43.16_suppl.8506","article-title":"Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFR m) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study","volume":"43","author":"Mok","year":"2025","journal-title":"J Clin Oncol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1200\/jco.2025.43.16_suppl.3000","article-title":"DB-1310, a HER3-targeted ADC, in pts with advanced solid tumors: Preliminary results from the phase 1\/2a trial","volume":"43","author":"Lisberg","year":"2025","journal-title":"J Clin Oncol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s12967-024-05133-7","article-title":"DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors","volume":"22","author":"Li","year":"2024","journal-title":"J Transl Med"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1158\/1538-7445.am2023-1884","article-title":"Abstract 1884: DB-1310, a novel Her3 targeting antibody-drug conjugate, exhibits therapeutic efficacy for solid tumors","volume":"83","author":"Li","year":"2023","journal-title":"Cancer Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-23-0198","article-title":"AMT-562, a novel HER3-targeting antibody-drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors","volume":"22","author":"Weng","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.18632\/genesandcancer.230","article-title":"CEACAMS 1, 5, and 6 in disease and cancer: interactions with pathogens","volume":"14","author":"Thomas","year":"2023","journal-title":"Genes Cancer"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-23-0461","article-title":"Characteristics of carcinoembryonic antigen-related cell adhesion molecules and their relationship to cancer","volume":"23","author":"Ma","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-013-9444-6","article-title":"Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis","volume":"32","author":"Beauchemin","year":"2013","journal-title":"Cancer Metastasis Rev"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-68170-0_10","article-title":"CEA-related CAMs","author":"Horst","year":"2004","journal-title":"Handb Exp Pharmacol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2006.08.008","article-title":"CEACAMs: their role in physiology and pathophysiology","volume":"18","author":"Kuespert","year":"2006","journal-title":"Curr Opin Cell Biol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1097\/coc.0000000000001116","article-title":"Wilms' tumor 1-associating protein promotes nonsmall-cell lung cancer through the expression of carcinoembryonic antigen-related cell adhesion molecule 5","volume":"47","author":"Liu","year":"2024","journal-title":"Am J Clin Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1177\/0300060520959478","article-title":"CEACAM5 stimulates the progression of non-small-cell lung cancer by promoting cell proliferation and migration","volume":"48","author":"Zhang","year":"2020","journal-title":"J Int Med Res"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008747","article-title":"Deregulation of the CEACAM expression pattern causes undifferentiated cell growth in human lung adenocarcinoma cells","volume":"5","author":"Singer","year":"2010","journal-title":"PloS One"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-4051","article-title":"Preclinical activity of SAR408701: A novel anti-CEACAM5-maytansinoid antibody-drug conjugate for the treatment of CEACAM5-positive epithelial tumors","volume":"26","author":"Decary","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107356","article-title":"The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape","volume":"184","author":"Lefebvre","year":"2023","journal-title":"Lung Cancer"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.e20013","article-title":"Assessment of carcinoembryonic antigen-related cell adhesion molecule 5 expression by immunohistochemistry in real-world clinical samples of non-small cell lung cancer","volume":"42","author":"Hsu","year":"2024","journal-title":"J Clin Oncol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2025.100844","article-title":"Evaluation of the safety, pharmacokinetics, and antitumor activity of tusamitamab ravtansine in patients with nonsquamous NSCLC with high or moderate expression of carcinoembryonic antigen-related cell adhesion molecule 5","volume":"6","author":"Gazzah","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.050","article-title":"Biomarker analysis from a phase 1\/1b study of tusamitamab ravtansine in patients with advanced non-small cell lung cancer","volume":"63","author":"Gazzah","year":"2026","journal-title":"Transl Oncol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03843-z","article-title":"Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, in metastatic colorectal cancer: a phase 1 trial","volume":"31","author":"Kopetz","year":"2025","journal-title":"Nat Med"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2025-ct117","article-title":"PROCEADE PanTumor: A phase 1b\/2, multicenter study of precemtabart tocentecan (M9140), an anti-CEACAM5 antibody-drug conjugate (ADC) with exatecan payload, in patients with advanced solid tumors","volume":"43","author":"Wainberg","year":"2025","journal-title":"J Clin Oncol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"5461","DOI":"10.1158\/1538-7445.am2025-5461","article-title":"Abstract 5461: BG-C477, a novel topoisomerase 1 inhibitor-based ADC, exhibits antitumor activity in carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)-expressing preclinical models","volume":"85","author":"He","year":"2025","journal-title":"Cancer Res"},{"key":"B123","doi-asserted-by":"crossref","DOI":"10.2174\/138945009788680374","article-title":"Defining the role of integrin alphavbeta6 in cancer","volume":"10","author":"Bandyopadhyay","year":"2009","journal-title":"Curr Drug Targets"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012346","article-title":"Integrin Alpha v Beta 6 (alphavbeta6) and Its Implications in Cancer Treatment","volume":"23","author":"Brzozowska","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.2543","article-title":"1919P Unveiling integrin beta-6 (IB6): real-world data from the IB6 expression and clinical outcomes in non-small cell lung cancer study","volume":"36","author":"Borgia","year":"2025","journal-title":"Ann Oncol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012346","article-title":"Integrin Alpha v Beta 6 (\u03b1v\u03b26) and Its Implications in Cancer Treatment","volume":"23","author":"Brzozowska","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B127","doi-asserted-by":"publisher","first-page":"8521","DOI":"10.1200\/jco.2024.42.16_suppl.8521","article-title":"Efficacy and safety of sigvotatug vedotin, an investigational ADC, in NSCLC: Updated phase 1 results (SGNB6A-001)","volume":"42","author":"Peters","year":"2024","journal-title":"J Clin Oncol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1453","article-title":"1398TiP Be6A Lung-01, a phase III study of sigvotatug vedotin (SV), an investigational antibody-drug conjugate (ADC) versus docetaxel in patients (pts) with previously treated non-small cell lung cancer (NSCLC)","volume":"35","author":"Peters","year":"2024","journal-title":"Ann Oncol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2596228","article-title":"Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score \u226550%: phase III study design","volume":"21","author":"Reck","year":"2025","journal-title":"Future Oncol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-09-0016","article-title":"Identification of Nectin-4 Oncoprotein as a Diagnostic and Therapeutic Target for Lung Cancer","volume":"69","author":"Takano","year":"2009","journal-title":"Cancer Res"},{"key":"B131","doi-asserted-by":"publisher","first-page":"e21119","DOI":"10.1200\/jco.2023.41.16_suppl.e21119","article-title":"Molecular characterization of nectin-4 in non-small cell lung cancer subtypes","volume":"41","author":"Hsu","year":"2023","journal-title":"J Clin Oncol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"217681","DOI":"10.2139\/ssrn.5167083","article-title":"Nectin-4 expression patterns and therapeutics in oncology","volume":"622","author":"Nikanjam","year":"2025","journal-title":"Cancer Lett"},{"key":"B133","doi-asserted-by":"publisher","first-page":"115603","DOI":"10.1016\/j.ejca.2025.115603","article-title":"Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1\/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study","volume":"227","author":"Muro","year":"2025","journal-title":"Eur J Cancer"},{"key":"B134","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1200\/jco.2025.43.16_suppl.3018","article-title":"Preliminary results from a first-in-human phase 1 dose escalation trial of ADRX-0706, a next generation Nectin-4 ADC, in subjects with advanced solid tumors","volume":"43","author":"Drakaki","year":"2025","journal-title":"J Clin Oncol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"e16567","DOI":"10.1200\/jco.2024.42.16_suppl.e16567","article-title":"A phase 1 study of BAT8007, an anti-nectin-4 monoclonal antibody-exatecan conjugate, in patients with advanced solid tumors","volume":"42","author":"Jiang","year":"2024","journal-title":"J Clin Oncol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1200\/jco.2025.43.5_suppl.807","article-title":"Phase I dose-escalation study of the next-generation nectin-4 targeting antibody\u2013drug conjugate CRB-701 (SYS6002) in US and UK patients with urothelial cancer and other solid tumors","volume":"43","author":"Perez","year":"2025","journal-title":"J Clin Oncol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-024-03060-x","article-title":"Recent insights into the therapeutic strategies targeting the pseudokinase PTK7 in cancer","volume":"43","author":"Dessaux","year":"2024","journal-title":"Oncogene"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-024-03060-x","article-title":"PTK7 expression is associated with lymph node metastasis, ALK and EGFR mutations in lung adenocarcinomas","volume":"35","author":"Jiang","year":"2020","journal-title":"Histol Histopathol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"e21105","DOI":"10.1200\/jco.2023.41.16_suppl.e21105","article-title":"Evaluation of the prevalence of MET and protein tyrosine kinase 7 expression in non-small cell lung cancer to evaluate overlap of ADC antigens","volume":"41","author":"Ansell","year":"2023","journal-title":"J Clin Oncol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-3757","article-title":"First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors","volume":"27","author":"Maitland","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B141","doi-asserted-by":"publisher","first-page":"108492","DOI":"10.1016\/j.lungcan.2025.108492","article-title":"A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer","volume":"202","author":"Cho","year":"2025","journal-title":"Lung Cancer"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.c.6861304.v2","article-title":"MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors","volume":"22","author":"Kong","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.665970","article-title":"PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies","volume":"12","author":"Jie","year":"2021","journal-title":"Front Immunol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"CT059","DOI":"10.1158\/1538-7445.am2024-ct059","article-title":"Abstract CT059: Phase 1b trial Mipasetamab Uzoptirine (ADCT-601-102) dose escalation in patients with advanced bone and soft tissue sarcomas","volume":"84","author":"Van Tine","year":"2024","journal-title":"Cancer Res"},{"key":"B145","doi-asserted-by":"publisher","first-page":"S209","DOI":"10.1016\/j.jtho.2019.08.414","article-title":"OA02.05 First-In-Human Phase 1\/2 Trial of Anti-AXL Antibody\u2013Drug Conjugate (ADC) Enapotamab Vedotin (EnaV) in Advanced NSCLC","volume":"14","author":"Ramalingam","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.jtho.2024.05.155","article-title":"PPD01.07 Phase 2 Trial of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, Alone or in Combination With Nivolumab in Patients With Non-Squamous NSCLC","volume":"19","author":"Rotow","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-24-0666","article-title":"DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity","volume":"25","author":"Takano","year":"2026","journal-title":"Mol Cancer Ther"},{"key":"B148","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41698-025-01016-2","article-title":"Mucin-1: a promising pan-cancer therapeutic target","volume":"9","author":"Grewal","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"TPS3165","DOI":"10.1158\/1538-7445.am2024-ct291","article-title":"A phase 1\/2, first-in-human study of DS-3939a in patients with advanced solid tumors: A new DXd ADC targeting TA-MUC1","volume":"42","author":"Yamamoto","year":"2024","journal-title":"J Clin Oncol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.1486","article-title":"917O DS-3939, a tumor-associated mucin 1 (TA-MUC1)\u2013directed antibody\u2013drug conjugate (ADC), in patients (pts) with advanced\/metastatic (adv\/met) solid tumors: Initial results from a first-in-human (FIH) study","volume":"36","author":"Patel","year":"2025","journal-title":"Ann Oncol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2021.11.005","article-title":"NaPi2b expression in a large surgical Non-Small Cell Lung Cancer (NSCLC) cohort","volume":"23","author":"Heynemann","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-3965","article-title":"Phase Ia Study of Anti-NaPi2b Antibody\u2013Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non\u2013Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer","volume":"26","author":"Gerber","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy023","article-title":"Anti-NaPi2b antibody\u2013drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study","volume":"29","author":"Banerjee","year":"2018","journal-title":"Ann Oncol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1200\/jco.2020.38.15_suppl.3549","article-title":"Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC)","volume":"38","author":"Richardson","year":"2020","journal-title":"J Clin Oncol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1016\/s0090-8258(22)01294-x","article-title":"Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer (076)","volume":"166","author":"Richardson","year":"2022","journal-title":"Gynecol Oncol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2024-esgo.1118","article-title":"#168 UPLIFT (ENGOT-Ov67\/GOG-3048): results from the phase 2 trial of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody-drug conjugate (ADC) in platinum-resistant ovarian cancer (PROC)","volume":"34","author":"Concin","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"B157","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1158\/1538-7445.am2024-2622","article-title":"Abstract 2622: TUB-040, a novel Napi2b-targeting ADC built with ethynylphosphonamidate conjugation chemistry, demonstrates high and long-lasting anti-tumor efficacy via Topoisomerase-I inhibition and excellent tolerability predictive of a wide therapeutic window in humans","volume":"84","author":"Schmitt","year":"2024","journal-title":"Cancer Res"},{"key":"B158","doi-asserted-by":"publisher","first-page":"TPS8660","DOI":"10.1200\/jco.2025.43.16_suppl.tps8660","article-title":"NAPISTAR 1-01: An international phase I\/II trial of the novel ADC TUB-040 in platinum-resistant ovarian cancer (PROC) and relapsed\/refractory adenocarcinoma non-small cell lung cancer (NSCLC)","volume":"43","author":"Van Gorp","year":"2025","journal-title":"J Clin Oncol"},{"key":"B159","doi-asserted-by":"publisher","first-page":"LB138","DOI":"10.1158\/1538-7445.am2025-lb138","article-title":"Abstract LB138: A novel dual-TOP1i ADC targeting NaPi2b designed for high efficacy and tolerability","volume":"85","author":"Attinger-Toller","year":"2025","journal-title":"Cancer Res"},{"key":"B160","doi-asserted-by":"publisher","first-page":"100917","DOI":"10.1016\/j.currproblcancer.2022.100917","article-title":"Folate Receptor as a Biomarker and Therapeutic Target in Solid Tumors","volume":"47","author":"Young","year":"2023","journal-title":"Curr Probl Cancer"},{"key":"B161","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.519","article-title":"Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance","volume":"3","author":"O'Shannessy","year":"2012","journal-title":"Oncotarget"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-4740","article-title":"First-in-Human Phase 1 Study of MORAb-202, an Antibody\u2013Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-\u03b1\u2013Positive Advanced Solid Tumors","volume":"27","author":"Shimizu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/s1556-0864(23)00329-5","article-title":"75TiP A multicenter, open-label, phase II trial evaluating the safety and efficacy of folate receptor alpha (FR\u03b1) antibody-drug conjugate (ADC) farletuzumab ecteribulin (FZEC*) in patients with previously treated, metastatic non-small cell lung cancer (NSCLC) adenocarcinoma (AC)","volume":"18","author":"Planchard","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"CT056","DOI":"10.1158\/1538-7445.am2023-ct056","article-title":"Abstract CT056: A multicenter, open-label phase 1\/2 trial evaluating the safety, tolerability, and efficacy of MORAb-202, a folate-receptor-alpha-targeting antibody-drug conjugate in patients with selected tumor types","volume":"83","author":"Wenham","year":"2023","journal-title":"Cancer Res"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2309169","article-title":"Mirvetuximab Soravtansine in FRalpha-Positive, Platinum-Resistant Ovarian Cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4701","article-title":"Over-expression of ROR2 and Wnt5a cooperatively correlates with unfavorable prognosis in patients with non-small cell lung cancer","volume":"6","author":"Lu","year":"2015","journal-title":"Oncotarget"},{"key":"B167","doi-asserted-by":"publisher","first-page":"TPS421","DOI":"10.1200\/jco.2024.42.3_suppl.tps421","article-title":"Cohort expansion from the phase 1 JEWEL-101 study investigating the tissue factor-targeting antibody-drug conjugate XB002 in patients with advanced solid tumors: Pancreatic and esophageal cancer cohorts","volume":"42","author":"Ulahannan","year":"2024","journal-title":"J Clin Oncol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.09.571","article-title":"P2.08-04 A Phase 1\/2 Dose Escalation and Dose Expansion Study of Ozuriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab","volume":"18","author":"Alexander","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B169","doi-asserted-by":"publisher","first-page":"6048","DOI":"10.1200\/jco.2025.43.16_suppl.6048","article-title":"Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally binding ROR2-ADC, in patients with heavily pretreated squamous cell carcinoma of the head and neck","volume":"43","author":"Adkins","year":"2025","journal-title":"J Clin Oncol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-3347","article-title":"Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-type Non-Small Cell Lung Cancer","volume":"31","author":"Trontzas","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf331","article-title":"Antibody drugs conjugates in non-small cell lung cancer: current status and challenges","volume":"30","author":"Syal","year":"2025","journal-title":"Oncologist"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2025.05.012","article-title":"Mechanisms of resistance to antibody-drug conjugates in cancers","volume":"63","author":"Murase","year":"2025","journal-title":"Respir Investig"},{"key":"B173","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13045-025-01752-9","article-title":"Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies","volume":"18","author":"Zhou","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00059","article-title":"First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01","volume":"41","author":"Shimizu","year":"2023","journal-title":"J Clin Oncol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.015","article-title":"PL02.11 Normalized Membrane Ratio of TROP2 by Quantitative Continuous Scoring is Predictive of Clinical Outcomes in TROPION-Lung 01","volume":"19","author":"Garassino","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B176","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-023-06174-8","article-title":"Radionuclide-based theranostics - a promising strategy for lung cancer","volume":"50","author":"Zhu","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B177","doi-asserted-by":"crossref","first-page":"e2415689","DOI":"10.1002\/advs.202415689","article-title":"A Novel Theranostic Strategy for Malignant Pulmonary Nodules by Targeted CECAM6 with (89)Zr\/(131)I-Labeled Tinurilimab","volume":"12","author":"Chen","year":"2025","journal-title":"Adv Sci"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.09.1358","article-title":"EP13.06-04 Radiotheranostics targeting Delta-Like Ligand 3 Expressing Small-Cell Lung Cancers","volume":"18","author":"Tendler","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B179","article-title":"Nectin-4-Targeted Radiotheranostics for Personalized Cancer Therapy: A Systematic Review","author":"Schafer","year":"2025","journal-title":"J Nucl Med"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2403614","article-title":"Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"B181","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N Engl J Med"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2307980","article-title":"Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"key":"B183","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1200\/jco.2025.43.16_suppl.3001","article-title":"Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with driver genomic alterations (GA) outside of classic EGFR mutations","volume":"43","author":"Yang","year":"2025","journal-title":"J Clin Oncol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.09.064","article-title":"OA10.04 Phase II Study of Iza-Bren (BL-B01D1) Combo With Osimertinib in EGFR Mutated Locally Advanced or Metastatic NSCLC Patients","volume":"20","author":"Zhou","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.4736","article-title":"Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer: Final Results From HERIZON-BTC-01","volume":"12","author":"Pant","year":"2026","journal-title":"JAMA Oncol"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-2180","article-title":"Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC","volume":"29","author":"Oh","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-25-0206","article-title":"Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I\/Ib Study","volume":"31","author":"Xue","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B188","doi-asserted-by":"publisher","first-page":"8604","DOI":"10.1200\/jco.2024.42.16_suppl.8604","article-title":"Efficacy and safety of MCLA-129, an EGFR\/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLC)","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"key":"B189","article-title":"Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial","volume":"332","author":"Fang","year":"2024","journal-title":"JAMA"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)02722-3","article-title":"Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China","volume":"405","author":"Xiong","year":"2025","journal-title":"Lancet"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.16_suppl.tps8129","article-title":"A global phase III, double-blind, randomized trial of BNT327\/PM8002 plus chemotherapy (chemo) compared to atezolizumab plus chemo in patients (pts) with first-line (1L) extensive-stage small cell lung cancer (ES-SCLC)","volume":"43","author":"Reck","year":"2025","journal-title":"J Clin Oncol"},{"key":"B192","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1200\/jco.2023.41.16_suppl.2536","article-title":"Phase Ib\/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors","volume":"41","author":"Guo","year":"2023","journal-title":"J Clin Oncol"},{"key":"B193","doi-asserted-by":"publisher","first-page":"TPS8652","DOI":"10.1200\/jco.2024.42.16_suppl.tps8652","article-title":"eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) expression <50%","volume":"42","author":"Johnson","year":"2024","journal-title":"J Clin Oncol"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.10.680","article-title":"647P A phase Ib\/II study of second-line cadonilimab, anlotinib and docetaxel in patients with checkpoint inhibitor (CPI)-experienced advanced non-small cell lung cancer","volume":"35","author":"Han","year":"2024","journal-title":"Ann Oncol"},{"key":"B195","doi-asserted-by":"publisher","first-page":"101470","DOI":"10.1016\/j.xcrm.2024.101470","article-title":"KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: A multicenter phase 2 trial","volume":"5","author":"Zhao","year":"2024","journal-title":"Cell Rep Med"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1016\/s1556-0864(25)00202-3","article-title":"7MO: A phase II trial of tobemstomig (tobe) + platinum-based chemotherapy (chemo) vs pembrolizumab (pembro) + chemo in patients (pts) with untreated locally advanced or metastatic non-small cell lung cancer (NSCLC)","volume":"20","author":"Nadal","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B197","doi-asserted-by":"publisher","first-page":"9050","DOI":"10.1200\/jco.2023.41.16_suppl.9050","article-title":"Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of AZD2936, a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-experienced advanced\/metastatic non-small-cell lung cancer (NSCLC): First report of ARTEMIDE-01","volume":"41","author":"Rohrberg","year":"2023","journal-title":"J Clin Oncol"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.2347","article-title":"1313MO Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patients (pts) with stage IIIB\u2013IV non-small-cell lung cancer (NSCLC) with previous anti-PD-(L)1 therapy","volume":"34","author":"Besse","year":"2023","journal-title":"Ann Oncol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-01929","article-title":"Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study","volume":"44","author":"Zhou","year":"2026","journal-title":"J Clin Oncol"},{"key":"B200","doi-asserted-by":"publisher","first-page":"TPS3156","DOI":"10.1200\/jco.2023.41.16_suppl.tps3156","article-title":"EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors","volume":"41","author":"Aggarwal","year":"2023","journal-title":"J Clin Oncol"},{"key":"B201","doi-asserted-by":"publisher","first-page":"TPS8593","DOI":"10.1200\/jco.2022.40.16_suppl.tps8593","article-title":"A phase 1\/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with mesenchymal epithelial transition factor (MET)-overexpressing NSCLC","volume":"40","author":"Drilon","year":"2022","journal-title":"J Clin Oncol"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2502099","article-title":"Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.3403","article-title":"2792TiP A phase Ib\/II study of gocatamig (MK-6070; HPN328) and ifinatamab deruxtecan for relapsed\/refractory extensive-stage small cell lung cancer (ES-SCLC)","volume":"36","author":"Bar","year":"2025","journal-title":"Ann Oncol"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.2974","article-title":"1077TiP TAK-500 as a single agent and in combination with pembrolizumab in patients (pts) with advanced solid tumors: Rationale and design of a phase I\/II study","volume":"34","author":"Singh","year":"2023","journal-title":"Ann Oncol"},{"key":"B205","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1200\/jco.2023.41.16_suppl.2538","article-title":"A phase 1\/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors","volume":"41","author":"Li","year":"2023","journal-title":"J Clin Oncol"},{"key":"B206","doi-asserted-by":"publisher","first-page":"5840","DOI":"10.1158\/1538-7445.am2025-5840","article-title":"Abstract 5840: PF-08046037, a PD-L1 targeted TLR7 agonist ISAC, drives innate immune activation and anti-tumor efficacy in preclinical in vitro and in vivo models","volume":"85","author":"Tampella","year":"2025","journal-title":"Cancer Res"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-3656","article-title":"Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I\/II Trial","volume":"28","author":"Boni","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B208","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1200\/jco.2020.38.15_suppl.3502","article-title":"CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer","volume":"38","author":"Johnson","year":"2020","journal-title":"J Clin Oncol"},{"key":"B209","doi-asserted-by":"publisher","first-page":"TPS1114","DOI":"10.1200\/jco.2023.41.16_suppl.tps1114","article-title":"A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors","volume":"41","author":"Hurvitz","year":"2023","journal-title":"J Clin Oncol"},{"key":"B210","doi-asserted-by":"publisher","first-page":"7005","DOI":"10.1158\/1538-7445.am2025-7005","article-title":"Abstract 7005: Discovery and characterization of DAC-1522, a novel Trop2-targeting degrader-antibody conjugate for precision oncology","volume":"85","author":"Chen","year":"2025","journal-title":"Cancer Res"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-24-0444","article-title":"Broad-Spectrum Efficacy of CEACAM6-Targeted Antibody-Drug Conjugate with BET Protein Degrader in Colorectal, Lung, and Breast Cancer Mouse Models","volume":"24","author":"Kogai","year":"2025","journal-title":"Mol Cancer Ther"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1814095\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T13:03:44Z","timestamp":1783515824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1814095\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":211,"alternative-id":["10.3389\/fonc.2026.1814095"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1814095","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"article-number":"1814095"}}